Fusion Antibodies PLC – Trading Update
Fusion Antibodies plc (AIM: FAB), a contract research organisation providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications, announces that the Company’s results for the year ended 31 March 2018 (“FY18”) will be announced on 16 August 2018. The results for FY18 are in line with current market expectations.
Current trading and prospects
Trading to date for the current financial period ending 31 March 2019 (“FY19”) has been slower than anticipated due to increasing competition and consequential pricing pressures, as well as a delay in securing some large contracts. Therefore, the Directors anticipate that the results for FY19 will be significantly behind current market expectations. However, the Directors believe that, based on the current pipeline, the Company will still achieve a modest year on year revenue growth.
We are pleased to confirm the laboratory capacity expansion has been completed, delivered on time and within budget, and the affinity maturation project is on schedule for completion in December 2018. The Company is continuing to build its sales and marketing capability internationally.
The Directors believe that these investments will enable the Company to continue to differentiate itself from its competitors and to win sophisticated, high value customer projects.